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Introduction
The acuteness-score, measured by the modified Anderson-Wilkins Acuteness Score, quantifies the acuteness of myocardial ischemia from the electrocardiogram (ECG) (1;2). In patients with STsegment elevation myocardial infarction (STEMI) treated with primary percutaneuous coronary intervention (pPCI), acute ischemia in their presenting ECG identifies salvage potential and predicts smaller infarct size independent of symptom durations (3-6). Distortion of the terminal portion of the QRS complexes in leads with ST elevation, due to myocardial vulnerability, has been defined as severe ischemia (7), is associated with rapid progression of necrosis and predicts adverse cardiovascular outcome (8-11). Thus, STEMI patients presenting with severe and acute ischemia on their ECG might particularly benefit from immediate coronary reperfusion. We assessed whether severe ischemia with or without acute ischemia is predictive of infarct size (IS), myocardial salvage index (MSI) and left ventricular ejection fraction (LVEF) in anterior versus inferior infarct locations.
Methods

Study population
Patients included in the MITOCARE study (12), a prospective, multicenter, randomized, doubleblind cardioprotection trial, were considered in the present study. In brief, the MITOCARE trial examined the potential for adjunctive TRO40303 to limit reperfusion injury in STEMI patients undergoing pPCI. Patients with first STEMI and symptom duration of <6 hours, underwent Cardiac Magnetic Resonance (CMR) imaging within 2 to 6 days after being treated with pPCI. In total, 165 included patients were randomized to receive either TRO40303 or placebo after coronary
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4 angiography. The results demonstrated that TRO40303 did not limit reperfusion injury of the infarcted myocardium (13).
ECG collection and ECG measurement
Electrocardiograms were recorded at hospital admission (baseline ECG). The electrocardiographic analyses were performed in the ECG Core Laboratory at the Rigshospitalet (Copenhagen, Denmark). ST-segment deviation was measured manually to the nearest 0.5 mm at the J-point in all
12 ECG leads using the TP-segment as the isoelectric line. Alternatively, the PR-segment was used if the TP-segment was not distinct. Patients with maximal ST elevation in leads V1 to V6 or I and aVL were classified as the anterior infarct group, while those with maximal ST elevation in leads II, III and aVF and/or ST-segment depression in V1-V3 were classified as the inferior infarct group.
The ECG investigators were blinded to all patient data.
The severity score
Severity of ischemia was determined by Sclarovsky-Birnbaum's grades of ischemia, which is based on the presence or absence of distortion of the terminal portion of the QRS complex in leads with ST-segment elevation (14). Distortion of the terminal QRS complex was defined as: 1: Absence of an S-wave in ≥ 2 adjacent leads that usually have a terminal S configuration (leads V1 to V3); or 2:
ST-J point amplitude ≥ 50% of the R-wave amplitude measured from the TP baseline in ≥ 2 adjacent leads in all other leads. In addition, leads with ST-segment elevation and negative T-waves were excluded. Detailed criteria of the Sclarovsky-Birnbaum's grades of ischemia are described elsewhere (15).
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We defined severe ischemia in the presence of QRS distortion in ≥2 contiguous leads and nonsevere ischemia in the absence of QRS distortion.
The acuteness-score
The ischemia acuteness-score was based on the modified Anderson-Wilkins acuteness score (1), which assesses changes in ST-T segments, T-waves and Q-waves. Each lead was designated an acuteness phase (1A, 1B, 2A or 2B) based on the presence or absence of a tall T-wave or an abnormal Q-wave; Phase 1A: tall T-wave and no abnormal Q-wave; Phase 1B: positive T-wave and no abnormal Q-wave; Phase 2A: tall T-wave and an abnormal Q-wave; Phase 2B: positive T-wave and an abnormal Q-wave (2). Criteria for abnormal Q-waves and tall T-waves are presented in table
1. The acuteness-score ranges from 1 (non-acute ischemia/least acute) to 4 (early ischemia/most acute) and was calculated from the formula:
Also, it has been shown that STEMI patients with ECG acuteness-score ≥3 and treated with pPCI, have better outcome independent of symptom durations (3;5;6). Accordingly, the ECG acutenessscore was dichotomized as ≥3 and <3. We defined acute ischemia as ECG acuteness-score ≥3 and non-acute ischemia as ECG acuteness-score <3.
ECG score analysis
Each lead with ST elevation ≥0.10 mV was considered for the severity and acuteness-score of ischemia.
A C C E P T E D M A N U S C R I P T Patients were then stratified according to severity and acuteness scores in 4 ischemia groups. Severe and non-acute ischemia; Non-severe and non-acute ischemia; Non-severe and acute ischemia; and
Severe and acute ischemia (Figure 1 ).
CMR Image Acquisition and analysis
Complete CMR examination was done in 93 patients. The CMR examinations were performed on a 1.5 T system from either Philips (Philips Healthcare, Best, The Netherlands), Siemens (Siemens AG, Erlangen, Germany) or General Electrics (GE Healthcare, Fairfield). All subjects were placed in a supine position, and images were acquired at end-expiratory breath hold with ECG gating.
Initial scout images were acquired to locate the heart. For assessment of myocardial area at risk For infarct visualization, long-and short-axis late gadolinium enhancement (LGE) images covering the LV from base to apex were acquired ≈15 minutes after injection of gadolinium. The LGE images were acquired using an inversion-recovery gradient-recalled echo sequence with a slice thickness of 8 mm with no slice gap. In-plane resolution was typically 1.5×1.5 mm. Inversion time was adjusted to null the signal from viable myocardium (17). Infarct size (% of LV) was quantified according to previously described methodology taking partial volume effects into account (18).
Microvascular obstruction (MVO) was defined as the hypo-enhanced myocardium within the hyper-enhanced regions of infarction and was expressed as % of LV.
Myocardial salvage index was calculated as (MaR-IS)/MaR. LVEF was measured by echocardiography 30 days after pPCI.
Biomarkers
Serial Creatine Kinase Myocardial Band (CK-MB) and Troponin (Tn) T and I were measured by a core lab (Firalis SAS, Huningue, France, http://www.firalis.com) from blood samples taken before and after pPCI. Infarct size was biochemically estimated by peak CK-MB and peak TnT levels.
Statistical analysis
Categorical data are presented as numbers (percentages) and continuous data are reported as mean ± SD or median (25 th -75 th interquartile). Baseline clinical and angiographic data were analyzed according to patients with severe or non-severe ischemia as well as acute or non-acute ischemia
groups. LV CMR measures and 30-day echocardiographic measures of LV were compared within the 4 ischemia groups for anterior vs. inferior STEMI. Groups were compared using Student's t test or ANOVA. Variables not normally distributed were log transformed in analysis models, as appropriate. All tests were two-sided and the level of statistical significance was defined as p< 0.05.
All analyses were performed using SPSS statistical software (SPSS version 20.0, SPSS Inc, Chicago, IL).
Results
Patient demographics
The ECG severity and acuteness-scores were measured in 147 and 165 patients, respectively. There were 86% male and mean age was 61 (±11) years old. Sixty five (40%) patients had anterior STEMI and 98 (60%) patients had non-anterior STEMI. Baseline characteristics according to patients with severe vs. non-severe ischemia and patients with acute vs. non-acute ischemia are shown in Table 2 .
LV outcomes according to electrocardiographic severity of ischemia
LV outcome measures by biomarkers (n=161), CMR (n=93) and echocardiography (n=146) in patients with severe vs. non-severe ischemia and patients with acute vs. non-acute ischemia are shown in Table 3 . Patients with severe ischemia had significantly larger infarct size estimated by peak CK-MB and CMR (21% (9-28) vs. 14% (10-19), p = 0.006) compared to those with nonsevere ischemia. MSI was significantly lower (50% (32-63) vs 56% (46-70), p = 0.035) in patients with severe ischemia compared to those with non-severe ischemia. Patients with severe ischemia
had also a significant higher extent of MVO and lower LVEF measured by CMR. There was no difference in N-terminal pro-brain natriuretic peptide (NTproBNP) levels or LVEF at follow up 30 days after pPCI in patients with severe vs. non-severe ischemia.
LV outcomes according to electrocardiographic acuteness of ischemia
Patients with acute ischemia had smaller infarct size (10% (9-16) vs. 15% (10-25), p = 0.004) and larger MSI (61% (55-74) vs. 50% (10-25), p = 0.013) compared to those with non-acute ischemia.
In addition, patients with acute ischemia had a significant higher LVEF (56% (51-64) vs. 52% (45-56), p = 0.001) and two-fold lower levels of NTproBNP (p = 0.009) 30 days after pPCI, Table 3 .
LV outcomes according to combination of severity and acuteness of ischemia
Four ECG ischemia groups were formed by combination of severity and acuteness-scores in 85 patients with available CMR data and resulted in 20 (23%) cases with severe and non-acute ischemia, 43 (51%) with non-severe and non-acute ischemia, 17 (20%) with non-severe and acute ischemia, and 5 (6%) patients with severe and acute ischemia. LV outcome measures by biomarkers, CMR and echocardiography, across the ECG ischemia groups for anterior and nonanterior STEMI are shown in Table 4 .
In patients with anterior STEMI, ECG measures of severity and acuteness of myocardial ischemia identified significant and stepwise differences in myocardial damage and function. Patients with severe ischemia and non-acute ischemia had the largest IS, smallest MSI and worst LVEF at follow up. In contrast, no differences in IS or MSI were observed in patients with inferior STEMI ( Figure   2 ).
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Discussion
Main findings
In the present study, we investigated the combination of the severity and acuteness of ischemia, obtained from admission ECG, in relation to left ventricular outcomes estimated by cardiac magnetic resonance in the acute phase, and by echocardiography 30 days after pPCI in patients with ST-segment elevation myocardial infarction. We demonstrated that patients with anterior STEMI and severe and non-acute ischemia on the admission ECG had the largest infarct size, smallest myocardial salvage and most impaired left ventricular function (Figure 2 ).
Possible electrophysiological mechanisms of ECG patterns
The process of evolving myocardial infarction begins rapidly after an acute coronary artery occlusion, where ischemia develops causing dynamic ECG changes. Initially tall T-waves develop.
These are followed by evolvement of ST-segment elevation, abnormal Q-waves, T-wave inversion, and finally resolution of the ST-segment elevation. The changes reflect 1-presence, location and extent (ST-segment elevation), 2-severity (distortion of the terminal portion of the QRS) and 3-timing of the infarction process (tall T-waves versus abnormal Q-waves). In leads with ST-segment elevation, distortion of the terminal portion of the QRS are explained by prolongation of the electrical conduction in the purkinje fibers in the ischemic zone, resulting in increase of R-wave amplitude in leads with terminal R-wave ( I, II, III, aVL, aVF, V4-V6) and decrease in S-wave amplitude in leads with terminal S-wave (leads V1-V3). Because purkinje fibers are believed to be less sensitive to ischemia than myocytes, they would in theory only be affected when the ischemia
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11 is severe and prolonged, hence resulting in distortion of the terminal portion of the QRS complex non-acute ischemia, a faster reperfusion strategy might only be beneficial in patients presenting with severe and acute ischemia on the ECG. The mechanism behind tall T-waves is not fully understood but a theory is that the repolarization of ischemic tissue is prolonged due to a delay in recovery of the membrane potential, which then causes tall T-waves (21). These changes are present temporarily after the onset of the infarction. Difference in gradients across the boundary between normal and ischemic myocardium changes the electrical currents in the myocardium causing STsegment elevation, while persistent Q-waves represent loss of electrically activity and are a sign of necrosis.
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Time delays for reperfusion therapy
Currently the triage for pPCI in STEMI is solely based on patient reported symptom durations.
Primary PCI is the preferred choice of reperfusion therapy if it is provided within 60-90 minutes of first medical contact in STEMI patients with symptom duration <12 hours (22-25). However, time of symptom onset estimation is often biased by inaccurate patient recollection and other factors that might pre-condition the ischemic myocardium leading to cardioprotection. The benefit from a faster reperfusion strategy by prehospital fibrinolysis has not been shown to be superior to pPCI in STEMI patients presenting early after symptom onset (26) . Prehospital fibrinolysis is shown to be non-superior over pPCI in clinical trials. However, some patients may have great benefit from this early approach of reperfusion. In cases of severe ischemia the progression of necrosis is very rapid and the jeopardized myocardium might evolve faster to myocardial infarction in patients presenting with severe and acute ischemia on the ECG. Consequently, these patients might have outstanding benefits from prehospital fibrinolysis, which basically reduces ischemia duration significantly, in addition to achieving reperfusion of the culprit artery onsite. Our findings illustrate that the combined application of ECG scores of the severity and acuteness of myocardial ischemia from the ECG is a useful clinical tool that identifies patients with severe and acute ischemia, who may potentially have the most benefit for a faster reperfusion strategy. More research is warranted to confirm this hypothesis. Severity score and acuteness-scores of myocardial ischemia from the prehospital ECG may be of value as a stratification and inclusion parameter in designing future clinical trials of reperfusion strategies in patients with STEMI (27) .
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Limitations
The present study has several limitations. Since this study was a sub-study from the MITOCARE trial, the study population is considered relatively small sized when stratified in 4 ECG groups. In the severe and acute ischemia group, there were no patients with anterior infarction. Thus, the analysis was based on the remaining 3 ECG groups in the anterior infarction group. Larger studies will be of great value, providing results based on statistical tests within the 4 groups. ECGs were analyzed manually by 3 independent investigators and no statistical reliability was performed.
However, a forth investigator (MS) has manually controlled 25 random ECGs, without finding any discrepancies between the investigators and MS. Due to the complexity of the ECG scores and availability of digital ECG, development of the automatic algorithms for acuteness-score (28) and severity of ischemia could facilitate clinical applications of these scores.
Conclusion
The applicability of ECG indices of severity and acuteness of myocardial ischemia to estimate myocardial damage and salvage potential in STEMI patients treated with pPCI, is confined to anterior myocardial infarction.
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